1643574-07-5Relevant academic research and scientific papers
PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF
-
Paragraph 0111; 0112; 0115, (2018/06/15)
Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-γ production in vivo. A compound represented by formula (I) [wherein X represents -CH=CH-, -NH-, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.
AZAINDOLE DERIVATIVE
-
Paragraph 0249; 0252, (2016/10/17)
Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.
HETEROCYCLIC BTK INHIBIT ORS
-
, (2015/11/09)
The invention provides compounds of Formula (I). Pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are de fined he E in. The compounds of the invention are useful for treating immunologic al and oncological conditions.
